In 2019, the European Society of Cardiology (ESC) provided an updated expert consensus statement, which noted that CYP2C19 genotyping in patients undergoing PCI with stable CAD or ACS on clopidogrel treatment may provide useful data for cardiovascular risk prediction for bleeding and ischemic events (23). This evidence concerns the gene CYP2C19 and coronary artery disorder.